Prognostic factors for survival in metastatic breast cancer during first-line paclitaxel chemotherapy

Anticancer Research

Volumn 23, Issue 2 C, 2003, Pages 1939-1942

  Nisman, Benjamin ^a   Barak, Vivian ^a   Hubert, Ayala ^a   Kaduri, Luna ^a   Lyass, Olga ^a   Baras, Mario ^a   Peretz, Tamar ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Metastatic breast cancer; Paclitaxel; Prognostic factors

Indexed keywords

HEMOGLOBIN; LACTATE DEHYDROGENASE; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DEMOGRAPHY; DISEASE COURSE; FEMALE; FOLLOW UP; HEMOGLOBIN DETERMINATION; HUMAN; LABORATORY TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HEMOGLOBINS; HUMANS; L-LACTATE DEHYDROGENASE; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 0037862057     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Berruti A, Tampellini M, Torta M, Buniva T, Gorzegno G and Dogliotti L: Prognostic value in predicting overall survival of two mucinous markers: CA15-3 and CA125 in breast cancer patients at first relapse of disease. Eur J Cancer 30A: 2082-2084, 1994.
2. Bohmer CH, Jager W and Lang N: CA125 measurement in the follow-up of breast cancer patients. Anticancer Res 17: 3099-3100, 1997.
3. Clark GM, Sledge GWJr, Osborne CK and McGuire WL: Survival from first recurrence: Relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 5: 55-61, 1987.
4. Colomer R, Ruibal A and Salvador L: Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 64: 1674-81, 1989.
5. Cox DR: Regression models and life-tables. J R Stat Soc 34: 187-202, 1972.
6. Fountzilas G, Athanassiades, Giannakakis T, Bafaloukos D, Karakousis K, Dombros N, Kosmidis P and Skarlos D: A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines. Eur J Cancer 32A: 47-51, 1996.
7. Gospodarowicz M, Mackillop W, O'Sullivan B, Sobin L, Henson D, Hutter RV and Wittekind C: Prognostic factors in clinical decision making: the future. Cancer 91: 1688-1695, 2001.
8. Greenberg PAC, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK and Buzdar AU: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14: 2197-2205, 1996.
9. Groopman JE and Itri LM: Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91: 1616-1634, 1999.
10. Hortobagyi GN, Smith TL, Legha SS, Swenerton KD, Gehan EA, Yap HY, Buzdar AU and Blumenschein GR: Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1: 776-786, 1983.
11. Jager W, Kissing A, Cilaci S, Melsheimer R and Lang N: Is an increase in CA 125 in breast cancer patients an indicator of pleural metastases? Br J Cancer 70: 493-495, 1994.
12. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
13. Kramer S, Jager W and Lang N: CA125 is an indicator for pleural metastases in breast cancer. Anticancer Res 17: 2967-2970, 1997.
14. Littlewood TJ: The impact of hemoglobin levels on treatment outcomes in patients with cancer. Sem Oncol 28: 49-53, 2001.
15. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B and Epoetin alfa study group: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19: 2865-2874, 2001.
16. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
17. Nabholtz J-M, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, Klaassen U, Namer M, Bonneterre J, Fumoleau P and Winograd B: Multicenter, ramdomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14: 1858-1867, 1996.
18. Norum LF, Erikstein B and Nustad K: Elevated CA 125 in breast cancer - a sign of advanced disease. Tumor Biol 22: 223-228, 2001.
19. Ohlhauser C, Bulzebruck H, Ebert W, Drings P and Wannenmacher M: Prognostic factors for survival in inoperable non-small-cell lung cancer: a multivariate regression analysis of 456 patients with radiation therapy. Onkologie 20: 126-131, 1997.
20. Schwartz MK: Enzymes as prognostic markers and therapeutic indicators in patients with cancer. Clin Chim Acta 206: 77-82, 1992.
21. Seidman AD, Reichman BS, Crown JPA, Yao TJ, Currie V, Hakes TB, Hudis CA, Gilewski TA, Baselga J, Forsythe P, Lepore J, Marks L, Fain K, Souhrada M, Onetto N, Arbuck S and Norton L: Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 13: 1152-1159, 1995.
22. Tampellini M, Berruti A, Gerbino A, Buniva T, Torta M, Gorzegno G, Faggiuolo R, Cannone R, Farris A, Destefanis M, Moro G, Deltetto F and Dogliotti L: Relationship between CA15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer 75: 698-702, 1997.
23. Tampellini M, Berruti A, Gorzegno G, Bitossi R, Bottini A, Durando A, De Matteis A, Farris A, Donadio M, De Fabiani E, Manzin E, Arese P, Sarobba MG, Castiglione F, Moro G, Bonazzi G, Nuzzo F, Massobrio M and Dogliotti L: Independent factors predict supranormal CA15-3 serum levels in advanced breast cancer patients at first disease relapse. Tumor Biol 22: 367-373, 2001.
24. Yamamoto N, Watanabe T, Katsumata N, Omuro Y, Ando M, Fukuda H, Takue Y, Narabayashi M, Adachi I and Takashima S: Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 16: 2401-2408, 1998.